Cancer Drug Maker Wants 10th Circuit Panel Or En Banc Court To Rehear Preemption

Mealey's (June 16, 2020, 4:44 PM EDT) -- DENVER — Genentech Inc. on June 12 petitioned the 10th Circuit U.S. Court of Appeals to rehear or rehear en banc arguments that claims about the company underfilling vials of the breast cancer drug Herceptin are preempted by federal law (In re:  Genentech, Inc., Herceptin [Trastuzumab] Marketing and Sales Practices Litigation, No. 19-5035, 10th Cir.)....

Attached Documents

Related Sections